Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Oct;110(2):507–517. doi: 10.1111/j.1476-5381.1993.tb13840.x

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

V C Jordan 1
PMCID: PMC2175926  PMID: 8242225

Abstract

Tamoxifen has been found to be a safe and effective treatment for all stages of breast cancer. Long term tamoxifen therapy is associated with some rare, but potentially serious, side effects so patients should be carefully monitored. However, long term tamoxifen therapy is also associated with a number of physiological benefits over and above its tumouristatic action. These benefits include a decrease in the development of contralateral breast cancer, the maintenance of bone density in postmenopausal women and a decrease in cardiovascular disease. The successful application of tamoxifen to treat breast cancer has increased enthusiasm to test its worth to prevent breast cancer. Although there are individual requests by patients for tamoxifen to prevent breast cancer, individual treatment is inappropriate. Tamoxifen can only be adequately evaluated as a preventive in randomized, double-blind clinical trials. These trials are in place and physicians should encourage women to participate and establish a new therapeutic option as rapidly as possible.

Full text

PDF
507

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson M., Storm H. H., Mouridsen H. T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991 Jul 17;83(14):1013–1017. doi: 10.1093/jnci/83.14.1013. [DOI] [PubMed] [Google Scholar]
  2. Arteaga C. L., Tandon A. K., Von Hoff D. D., Osborne C. K. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988 Jul 15;48(14):3898–3904. [PubMed] [Google Scholar]
  3. Atlante G., Pozzi M., Vincenzoni C., Vocaturo G. Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol. 1990 Jun;37(3):378–380. doi: 10.1016/0090-8258(90)90371-q. [DOI] [PubMed] [Google Scholar]
  4. Beck M., Mills P. V. Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1833–1834. [PubMed] [Google Scholar]
  5. Bentley C. R., Davies G., Aclimandos W. A. Tamoxifen retinopathy: a rare but serious complication. BMJ. 1992 Feb 22;304(6825):495–496. doi: 10.1136/bmj.304.6825.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990 Sep;9(9):2811–2818. doi: 10.1002/j.1460-2075.1990.tb07469.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boccardo F., Rubagotti A., Bruzzi P., Cappellini M., Isola G., Nenci I., Piffanelli A., Scanni A., Sismondi P., Santi L. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J Clin Oncol. 1990 Aug;8(8):1310–1320. doi: 10.1200/JCO.1990.8.8.1310. [DOI] [PubMed] [Google Scholar]
  8. Bonte J., Ide P., Billiet G., Wynants P. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. 1981 Apr;11(2):140–161. doi: 10.1016/s0090-8258(81)80003-0. [DOI] [PubMed] [Google Scholar]
  9. Broens J., Mouridsen H. T., Soerensen H. M. Tamoxifen in advanced endometrial carcinoma. Cancer Chemother Pharmacol. 1980;4(3):213–213. doi: 10.1007/BF00254022. [DOI] [PubMed] [Google Scholar]
  10. Buchanan R. B., Blamey R. W., Durrant K. R., Howell A., Paterson A. G., Preece P. E., Smith D. C., Williams C. J., Wilson R. G. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326–1330. doi: 10.1200/JCO.1986.4.9.1326. [DOI] [PubMed] [Google Scholar]
  11. Butta A., MacLennan K., Flanders K. C., Sacks N. P., Smith I., McKinna A., Dowsett M., Wakefield L. M., Sporn M. B., Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992 Aug 1;52(15):4261–4264. [PubMed] [Google Scholar]
  12. Chaudary M. A., Millis R. R., Hoskins E. O., Halder M., Bulbrook R. D., Cuzick J., Hayward J. L. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984 Sep;71(9):711–714. doi: 10.1002/bjs.1800710924. [DOI] [PubMed] [Google Scholar]
  13. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Colletta A. A., Wakefield L. M., Howell F. V., van Roozendaal K. E., Danielpour D., Ebbs S. R., Sporn M. B., Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer. 1990 Sep;62(3):405–409. doi: 10.1038/bjc.1990.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Corley D., Rowe J., Curtis M. T., Hogan W. M., Noumoff J. S., Livolsi V. A. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992 Jan;79(1):111–116. [PubMed] [Google Scholar]
  16. Cummings F. J., Gray R., Davis T. E., Tormey D. C., Harris J. E., Falkson G., Arseneau J. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med. 1985 Sep;103(3):324–329. doi: 10.7326/0003-4819-103-3-324. [DOI] [PubMed] [Google Scholar]
  17. Cuzick J., Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985 Aug 3;2(8449):282–282. doi: 10.1016/s0140-6736(85)90338-1. [DOI] [PubMed] [Google Scholar]
  18. DAO T. L. The role of ovarian hormones in initiating the induction of mammary cancer in rats by polynuclear hydrocarbons. Cancer Res. 1962 Sep;22:973–981. [PubMed] [Google Scholar]
  19. De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991 Oct;36(2):127–130. doi: 10.1016/0020-7292(91)90767-y. [DOI] [PubMed] [Google Scholar]
  20. Dilts P. V., Jr, Hopkins M. P., Chang A. E., Cody R. L. Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):167–168. doi: 10.1016/0002-9378(92)91854-4. [DOI] [PubMed] [Google Scholar]
  21. Dragan Y. P., Xu Y. D., Pitot H. C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med. 1991 Jan;20(1):15–26. doi: 10.1016/0091-7435(91)90003-m. [DOI] [PubMed] [Google Scholar]
  22. Falkson H. C., Gray R., Wolberg W. H., Gillchrist K. W., Harris J. E., Tormey D. C., Falkson G. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990 Apr;8(4):599–607. doi: 10.1200/JCO.1990.8.4.599. [DOI] [PubMed] [Google Scholar]
  23. Fentiman I. S., Caleffi M., Rodin A., Murby B., Fogelman I. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer. 1989 Aug;60(2):262–264. doi: 10.1038/bjc.1989.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Fisher B., Brown A., Wolmark N., Redmond C., Wickerham D. L., Wittliff J., Dimitrov N., Legault-Poisson S., Schipper H., Prager D. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649–654. doi: 10.7326/0003-4819-106-5-649. [DOI] [PubMed] [Google Scholar]
  25. Fisher B., Redmond C., Legault-Poisson S., Dimitrov N. V., Brown A. M., Wickerham D. L., Wolmark N., Margolese R. G., Bowman D., Glass A. G. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005–1018. doi: 10.1200/JCO.1990.8.6.1005. [DOI] [PubMed] [Google Scholar]
  26. Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res. 1992 May 1;52(9):2371–2383. [PubMed] [Google Scholar]
  27. Ford M. R., Turner M. J., Wood C., Soutter W. P. Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol. 1988 May;158(5):1119–1119. doi: 10.1016/0002-9378(88)90233-5. [DOI] [PubMed] [Google Scholar]
  28. Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Silfverswärd C., Skoog L., Somell A., Theve T., Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989 Jan 21;1(8630):117–120. doi: 10.1016/s0140-6736(89)91141-0. [DOI] [PubMed] [Google Scholar]
  29. Furr B. J., Jordan V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127–205. doi: 10.1016/0163-7258(84)90043-3. [DOI] [PubMed] [Google Scholar]
  30. Gagliardi A., Collins D. C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993 Feb 1;53(3):533–535. [PubMed] [Google Scholar]
  31. Gail M. H., Brinton L. A., Byar D. P., Corle D. K., Green S. B., Schairer C., Mulvihill J. J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989 Dec 20;81(24):1879–1886. doi: 10.1093/jnci/81.24.1879. [DOI] [PubMed] [Google Scholar]
  32. Gal D., Kopel S., Bashevkin M., Lebowicz J., Lev R., Tancer M. L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report. Gynecol Oncol. 1991 Aug;42(2):120–123. doi: 10.1016/0090-8258(91)90330-8. [DOI] [PubMed] [Google Scholar]
  33. Gerner E. W. Ocular toxicity of tamoxifen. Ann Ophthalmol. 1989 Nov;21(11):420–423. [PubMed] [Google Scholar]
  34. Gorski J., Toft D., Shyamala G., Smith D., Notides A. Hormone receptors: studies on the interaction of estrogen with the uterus. Recent Prog Horm Res. 1968;24:45–80. doi: 10.1016/b978-1-4831-9827-9.50008-3. [DOI] [PubMed] [Google Scholar]
  35. Gottardis M. M., Jordan V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987 Aug 1;47(15):4020–4024. [PubMed] [Google Scholar]
  36. Gottardis M. M., Jordan V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988 Sep 15;48(18):5183–5187. [PubMed] [Google Scholar]
  37. Gottardis M. M., Robinson S. P., Satyaswaroop P. G., Jordan V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988 Feb 15;48(4):812–815. [PubMed] [Google Scholar]
  38. Green S. Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):747–751. doi: 10.1016/0960-0760(90)90415-h. [DOI] [PubMed] [Google Scholar]
  39. Griffiths M. F. Tamoxifen retinopathy at low dosage. Am J Ophthalmol. 1987 Aug 15;104(2):185–186. doi: 10.1016/0002-9394(87)90014-6. [DOI] [PubMed] [Google Scholar]
  40. Groom G. V., Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol. 1976 Sep;70(3):421–428. doi: 10.1677/joe.0.0700421. [DOI] [PubMed] [Google Scholar]
  41. Gullino P. M., Pettigrew H. M., Grantham F. H. N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst. 1975 Feb;54(2):401–414. [PubMed] [Google Scholar]
  42. Gusberg S. B. Tamoxifen for breast cancer: associated endometrial cancer. Cancer. 1990 Apr 1;65(7):1463–1464. doi: 10.1002/1097-0142(19900401)65:7<1463::aid-cncr2820650702>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  43. HUGGINS C., GRAND L. C., BRILLANTES F. P. Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature. 1961 Jan 21;189:204–207. doi: 10.1038/189204a0. [DOI] [PubMed] [Google Scholar]
  44. Han X. L., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992 Mar 1;52(5):1360–1363. [PubMed] [Google Scholar]
  45. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 1988 Sep 3;2(8610):563–563. doi: 10.1016/s0140-6736(88)92675-x. [DOI] [PubMed] [Google Scholar]
  46. Harper M. J., Walpole A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil. 1967 Feb;13(1):101–119. doi: 10.1530/jrf.0.0130101. [DOI] [PubMed] [Google Scholar]
  47. Harper M. J., Walpole A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature. 1966 Oct 1;212(5057):87–87. doi: 10.1038/212087a0. [DOI] [PubMed] [Google Scholar]
  48. Harper M. J., Walpole A. L. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol. 1967 Jan;37(1):83–92. doi: 10.1677/joe.0.0370083. [DOI] [PubMed] [Google Scholar]
  49. Hendrick A., Subramanian V. P. Tamoxifen and thromboembolism. JAMA. 1980 Feb 8;243(6):514–515. [PubMed] [Google Scholar]
  50. Horwitz R. I., Feinstein A. R. Estrogens and endometrial cancer. Responses to arguments and current status of an epidemiologic controversy. Am J Med. 1986 Sep;81(3):503–507. doi: 10.1016/0002-9343(86)90306-2. [DOI] [PubMed] [Google Scholar]
  51. Huynh H. T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 1993 Apr 15;53(8):1727–1730. [PubMed] [Google Scholar]
  52. Ingle J. N., Ahmann D. L., Green S. J., Edmonson J. H., Bisel H. F., Kvols L. K., Nichols W. C., Creagan E. T., Hahn R. G., Rubin J. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16–21. doi: 10.1056/NEJM198101013040104. [DOI] [PubMed] [Google Scholar]
  53. Jensen E. V., Block G. E., Smith S., Kyser K., DeSombre E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 1971 Dec;34:55–70. [PubMed] [Google Scholar]
  54. Jordan V. C., Allen K. E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 1980 Feb;16(2):239–251. doi: 10.1016/0014-2964(80)90156-5. [DOI] [PubMed] [Google Scholar]
  55. Jordan V. C. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984 Dec;36(4):245–276. [PubMed] [Google Scholar]
  56. Jordan V. C., Collins M. M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977 Nov;75(2):305–316. doi: 10.1677/joe.0.0750305. [DOI] [PubMed] [Google Scholar]
  57. Jordan V. C., Dix C. J., Naylor K. E., Prestwich G., Rowsby L. Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health. 1978 Mar-May;4(2-3):363–390. doi: 10.1080/15287397809529666. [DOI] [PubMed] [Google Scholar]
  58. Jordan V. C., Dowse L. J. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol. 1976 Feb;68(02):297–303. doi: 10.1677/joe.0.0680297. [DOI] [PubMed] [Google Scholar]
  59. Jordan V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 1976 Jun;12(6):419–424. doi: 10.1016/0014-2964(76)90030-x. [DOI] [PubMed] [Google Scholar]
  60. Jordan V. C., Fritz N. F., Langan-Fahey S., Thompson M., Tormey D. C. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991 Oct 16;83(20):1488–1491. doi: 10.1093/jnci/83.20.1488. [DOI] [PubMed] [Google Scholar]
  61. Jordan V. C., Fritz N. F., Tormey D. C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 1987 Aug 15;47(16):4517–4519. [PubMed] [Google Scholar]
  62. Jordan V. C., Jaspan T. Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol. 1976 Mar;68(3):453–460. doi: 10.1677/joe.0.0680453. [DOI] [PubMed] [Google Scholar]
  63. Jordan V. C., Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer. 1975 Mar;11(3):205–206. doi: 10.1016/0014-2964(75)90119-x. [DOI] [PubMed] [Google Scholar]
  64. Jordan V. C., Lababidi M. K., Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst. 1991 Apr 3;83(7):492–496. doi: 10.1093/jnci/83.7.492. [DOI] [PubMed] [Google Scholar]
  65. Jordan V. C., Lababidi M. K., Mirecki D. M. Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer. 1990;26(6):718–721. doi: 10.1016/0277-5379(90)90125-d. [DOI] [PubMed] [Google Scholar]
  66. Jordan V. C. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat. 1983;3 (Suppl):S73–S86. doi: 10.1007/BF01855131. [DOI] [PubMed] [Google Scholar]
  67. Jordan V. C. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat. 1990 May;15(3):125–136. doi: 10.1007/BF01806350. [DOI] [PubMed] [Google Scholar]
  68. Jordan V. C., Murphy C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev. 1990 Nov;11(4):578–610. doi: 10.1210/edrv-11-4-578. [DOI] [PubMed] [Google Scholar]
  69. Jordan V. C., Prestwich G. Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol. 1977 Sep;8(3):179–188. doi: 10.1016/0303-7207(77)90090-9. [DOI] [PubMed] [Google Scholar]
  70. Jordan V. C. Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J Reprod Fertil. 1975 Feb;42(2):251–258. doi: 10.1530/jrf.0.0420251. [DOI] [PubMed] [Google Scholar]
  71. Jordan V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat. 1988 Jul;11(3):197–209. doi: 10.1007/BF01807278. [DOI] [PubMed] [Google Scholar]
  72. Kaiser-Kupfer M. I., Kupfer C., Rodrigues M. M. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981 Jan;88(1):89–93. doi: 10.1016/s0161-6420(81)35071-4. [DOI] [PubMed] [Google Scholar]
  73. Kaiser-Kupfer M. I., Lippman M. E. Tamoxifen retinopathy. Cancer Treat Rep. 1978 Mar;62(3):315–320. [PubMed] [Google Scholar]
  74. Kalef-Ezra J., Glaros D., Klouvas G., Hatzikonstantinou J., Karantanas A., Siamopoulos K. C., Pavlidis N. New evidence that tamoxifen does not induce osteoporosis: a nuclear activation analysis and absorptiometry study. Br J Radiol. 1992 May;65(773):417–420. doi: 10.1259/0007-1285-65-773-417. [DOI] [PubMed] [Google Scholar]
  75. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
  76. Langan-Fahey S. M., Tormey D. C., Jordan V. C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer. 1990;26(8):883–888. doi: 10.1016/0277-5379(90)90191-u. [DOI] [PubMed] [Google Scholar]
  77. Lathrop A. E., Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res. 1916 Jan;1(1):1–19. [PubMed] [Google Scholar]
  78. Lerner L. J., Jordan V. C. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990 Jul 15;50(14):4177–4189. [PubMed] [Google Scholar]
  79. Lipton A., Harvey H. A., Hamilton R. W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984 Jun;68(6):887–889. [PubMed] [Google Scholar]
  80. Longstaff S., Sigurdsson H., O'Keeffe M., Ogston S., Preece P. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1805–1808. doi: 10.1016/0277-5379(89)90351-9. [DOI] [PubMed] [Google Scholar]
  81. Love R. R., Cameron L., Connell B. L., Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991 Sep;151(9):1842–1847. [PubMed] [Google Scholar]
  82. Love R. R., Mazess R. B., Barden H. S., Epstein S., Newcomb P. A., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992 Mar 26;326(13):852–856. doi: 10.1056/NEJM199203263261302. [DOI] [PubMed] [Google Scholar]
  83. Love R. R., Mazess R. B., Tormey D. C., Barden H. S., Newcomb P. A., Jordan V. C. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat. 1988 Dec;12(3):297–302. doi: 10.1007/BF01811242. [DOI] [PubMed] [Google Scholar]
  84. Love R. R., Newcomb P. A., Wiebe D. A., Surawicz T. S., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990 Aug 15;82(16):1327–1332. doi: 10.1093/jnci/82.16.1327. [DOI] [PubMed] [Google Scholar]
  85. Love R. R., Surawicz T. S., Williams E. C. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992 Feb;152(2):317–320. [PubMed] [Google Scholar]
  86. Love R. R. The Wisconsin Tamoxifen Study: toxicity in node-negative postmenopausal women. Cancer Invest. 1988;6(5):601–605. doi: 10.3109/07357908809082126. [DOI] [PubMed] [Google Scholar]
  87. Love R. R., Wiebe D. A., Newcomb P. A., Cameron L., Leventhal H., Jordan V. C., Feyzi J., DeMets D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991 Dec 1;115(11):860–864. doi: 10.7326/0003-4819-115-11-860. [DOI] [PubMed] [Google Scholar]
  88. Lyman S. D., Jordan V. C. Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol. 1985 Aug 1;34(15):2787–2794. doi: 10.1016/0006-2952(85)90580-5. [DOI] [PubMed] [Google Scholar]
  89. Magriples U., Naftolin F., Schwartz P. E., Carcangiu M. L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485–490. doi: 10.1200/JCO.1993.11.3.485. [DOI] [PubMed] [Google Scholar]
  90. Manni A., Pearson O. H. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):779–785. [PubMed] [Google Scholar]
  91. McDonald C. C., Stewart H. J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991 Aug 24;303(6800):435–437. doi: 10.1136/bmj.303.6800.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Morrow M. Pre-cancerous breast lesions: implications for breast cancer prevention trials. Int J Radiat Oncol Biol Phys. 1992;23(5):1071–1078. doi: 10.1016/0360-3016(92)90915-5. [DOI] [PubMed] [Google Scholar]
  93. Nayfield S. G., Karp J. E., Ford L. G., Dorr F. A., Kramer B. S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991 Oct 16;83(20):1450–1459. doi: 10.1093/jnci/83.20.1450. [DOI] [PubMed] [Google Scholar]
  94. Nevasaari K., Heikkinen M., Taskinen P. J. Tamoxifen and thrombosis. Lancet. 1978 Oct 28;2(8096):946–947. doi: 10.1016/s0140-6736(78)91668-9. [DOI] [PubMed] [Google Scholar]
  95. Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E. Tamoxifen and the uterus and endometrium. Lancet. 1989 Feb 18;1(8634):375–375. [PubMed] [Google Scholar]
  96. Noguchi S., Motomura K., Inaji H., Imaoka S., Koyama H. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer. 1993 Jul 1;72(1):131–136. doi: 10.1002/1097-0142(19930701)72:1<131::aid-cncr2820720125>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  97. Noguchi S., Motomura K., Inaji H., Imaoka S., Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer. 1993 Feb 15;71(4):1266–1272. doi: 10.1002/1097-0142(19930215)71:4<1266::aid-cncr2820710416>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  98. Nuovo M. A., Nuovo G. J., McCaffrey R. M., Levine R. U., Barron B., Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol. 1989;8(2):125–131. doi: 10.1097/00004347-198906000-00005. [DOI] [PubMed] [Google Scholar]
  99. Paterson A. H., Hanson J., Pritchard K. I., Sansregret E., Dahrouge S., McDermot R. S., Fine S., White D. F., Trudeau M., Stewart D. J. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol. 1990 Dec;17(6 Suppl 9):52–62. [PubMed] [Google Scholar]
  100. Pavlidis N. A., Petris C., Briassoulis E., Klouvas G., Psilas C., Rempapis J., Petroutsos G. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992 Jun 15;69(12):2961–2964. doi: 10.1002/1097-0142(19920615)69:12<2961::aid-cncr2820691215>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  101. Pham T. A., Elliston J. F., Nawaz Z., McDonnell D. P., Tsai M. J., O'Malley B. W. Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3125–3129. doi: 10.1073/pnas.88.8.3125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Pham T. A., Hwung Y. P., Santiso-Mere D., McDonnell D. P., O'Malley B. W. Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. Mol Endocrinol. 1992 Jul;6(7):1043–1050. doi: 10.1210/mend.6.7.1508220. [DOI] [PubMed] [Google Scholar]
  103. Pollak M. N., Huynh H. T., Lefebvre S. P. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat. 1992;22(1):91–100. doi: 10.1007/BF01833337. [DOI] [PubMed] [Google Scholar]
  104. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  106. Pritchard K. I., Thomson D. B., Myers R. E., Sutherland D. J., Mobbs B. G., Meakin J. W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):787–796. [PubMed] [Google Scholar]
  107. Pugesgaard T., Von Eyben F. E. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer. 1986 Jul 15;58(2):383–386. doi: 10.1002/1097-0142(19860715)58:2<383::aid-cncr2820580232>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  108. Ritchie L. D., Grant S. M. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. BMJ. 1989 May 6;298(6682):1253–1253. doi: 10.1136/bmj.298.6682.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Robinson S. P., Langan-Fahey S. M., Johnson D. A., Jordan V. C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991 Jan-Feb;19(1):36–43. [PubMed] [Google Scholar]
  110. Rose D. P., Chlebowski R. T., Connolly J. M., Jones L. A., Wynder E. L. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res. 1992 Oct 1;52(19):5386–5390. [PubMed] [Google Scholar]
  111. Rose D. P., Davis T. E. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet. 1977 Jun 4;1(8023):1174–1176. doi: 10.1016/s0140-6736(77)92716-7. [DOI] [PubMed] [Google Scholar]
  112. Saphner T., Tormey D. C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991 Feb;9(2):286–294. doi: 10.1200/JCO.1991.9.2.286. [DOI] [PubMed] [Google Scholar]
  113. Satyaswaroop P. G., Zaino R. J., Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 1984 Sep;44(9):4006–4010. [PubMed] [Google Scholar]
  114. Schreiber A. B., Winkler M. E., Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science. 1986 Jun 6;232(4755):1250–1253. doi: 10.1126/science.2422759. [DOI] [PubMed] [Google Scholar]
  115. Schwartzbaum J. A., Hulka B. S., Fowler W. C., Jr, Kaufman D. G., Hoberman D. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol. 1987 Nov;126(5):851–860. doi: 10.1093/oxfordjournals.aje.a114722. [DOI] [PubMed] [Google Scholar]
  116. Skidmore J., Walpole A. L., Woodburn J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J Endocrinol. 1972 Feb;52(2):289–298. doi: 10.1677/joe.0.0520289. [DOI] [PubMed] [Google Scholar]
  117. Sunderland M. C., Osborne C. K. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991 Jul;9(7):1283–1297. doi: 10.1200/JCO.1991.9.7.1283. [DOI] [PubMed] [Google Scholar]
  118. Swenerton K. D. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):805–811. [PubMed] [Google Scholar]
  119. Tenni P., Lalich D. L., Byrne M. J. Life threatening interaction between tamoxifen and warfarin. BMJ. 1989 Jan 14;298(6666):93–93. doi: 10.1136/bmj.298.6666.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Terenius L. Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol (Copenh) 1971 Mar;66(3):431–447. doi: 10.1530/acta.0.0660431. [DOI] [PubMed] [Google Scholar]
  121. Tormey D. C., Gray R., Abeloff M. D., Roseman D. L., Gilchrist K. W., Barylak E. J., Stott P., Falkson G. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992 Dec;10(12):1848–1856. doi: 10.1200/JCO.1992.10.12.1848. [DOI] [PubMed] [Google Scholar]
  122. Tormey D. C., Jordan V. C. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat. 1984;4(4):297–302. doi: 10.1007/BF01806042. [DOI] [PubMed] [Google Scholar]
  123. Tormey D. C., Rasmussen P., Jordan V. C. Long-term adjuvant tamoxifen study: clinical update. Breast Cancer Res Treat. 1987;9(2):157–158. doi: 10.1007/BF01807370. [DOI] [PubMed] [Google Scholar]
  124. Turcot-Lemay L., Kelly P. A. Characterization of estradiol, progesterone, and prolactin receptors in nitrosomethylurea-induced mammary tumors and effect of antiestrogen treatment on the development and growth of these tumors. Cancer Res. 1980 Sep;40(9):3232–3240. [PubMed] [Google Scholar]
  125. Turken S., Siris E., Seldin D., Flaster E., Hyman G., Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989 Jul 19;81(14):1086–1088. doi: 10.1093/jnci/81.14.1086. [DOI] [PubMed] [Google Scholar]
  126. Vinding T., Nielsen N. V. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol (Copenh) 1983 Feb;61(1):45–50. doi: 10.1111/j.1755-3768.1983.tb01393.x. [DOI] [PubMed] [Google Scholar]
  127. Ward H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Welshons W. V., Lieberman M. E., Gorski J. Nuclear localization of unoccupied oestrogen receptors. Nature. 1984 Feb 23;307(5953):747–749. doi: 10.1038/307747a0. [DOI] [PubMed] [Google Scholar]
  129. White I. N., de Matteis F., Davies A., Smith L. L., Crofton-Sleigh C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992 Dec;13(12):2197–2203. doi: 10.1093/carcin/13.12.2197. [DOI] [PubMed] [Google Scholar]
  130. Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 1993 Feb;14(2):315–317. doi: 10.1093/carcin/14.2.315. [DOI] [PubMed] [Google Scholar]
  131. Wilson A. J., Tehrani F., Baum M. Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors. Br J Surg. 1982 Mar;69(3):121–125. doi: 10.1002/bjs.1800690302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES